App-Quantinova.ai

With a little help from CD4 T cells in adoptive T-cell transfer

Else M. Inderberg - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adenovirus-transduced allogeneic dendritic cells for cancer immunotherapy

Magnus Essand - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

TEM8/ANTXR1 specific T cells co-target tumor stem cells and tumor vasculature in triple-negative breast cancer

Tiara Byrd - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system

Armin Ehninger - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

GPC3-specific chimeric antigen receptor T cell in combination with Sorafenib as a novel therapeutic treatment for hepatocellular carcinoma

Thu Le Trinh - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

Discovery and validation of a novel checkpoint target preferentially expressed in the tumor microenvironment

Narendiran Rajasekaran - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma

Matthew R. Farren - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anti-CTLA4

CD70 immune checkpoint ligand is associated with the epithelial-to-mesenchymal transition in non-small cell lung cancer

Sandra Ortiz-Cuaran - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Ibrutinib enhances antitumor activity in solid tumors when combined with checkpoint inhibitors

Jeff Hsu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ibrutinib

Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade

Shu Wang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine

Carolina Fazio - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

guadecitabine

IFNgamma regulates PD-L1 expression through activating IRF1 transcription in tumor cells

Chunwan Lu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

HDAC6, new role as master regulator of PD-L1 and immune-related pathways

Tessa Knox - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anti-CTLA4

Patient-derived tumor xenografts in humanized NSG-SGM3 mice: a new immuno-oncology platform

Li-Chin Yao - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Possible prediction of tumor specific checkpoint inhibitor response based on TCGA somatic mutation load

Leandro Machado Colli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer

Jong Woo Lee - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with PD-L1 treatment in vivo

Kathryn Fraser - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon Gamma

RNAi discovery platform to identify novel genes that prevent immune surveillance in pancreatic ductal adenocarcinoma (PDAC)

Antonio Sorrentino - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model

Caroline Sola - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Monalizumab

Discovery and characterization of new original blocking antibodies targeting the CD73 immune checkpoint for cancer immunotherapy

Marc Giraudon Paoli - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Adenosine

Filters

41730 Abstracts